October 2015, Vol 6, No 9

Much attention is given to how bad news affects patients with cancer. Yet, little is known about the experience of physicians and what is required by them to deliver this news.

As patients, providers, payers, and policymakers continue to seek ways to assess the value of cancer therapies by balancing clinical benefits and treatment costs, a number of tools have been released to define the value of medicines.

Patients with early breast cancer and a low Oncotype DX recurrence score can safely receive treatment with hormone therapy alone and avoid chemotherapy, according to results of the TAILORx trial, which was sponsored by the National Cancer Institute.